Cancidas is a brand name of caspofungin, approved by the FDA in the following formulation(s):
CANCIDAS (caspofungin acetate - injectable; iv (infusion))
Manufacturer: MERCK
Approval date: January 26, 2001
Strength(s): 50MG/VIAL [RLD], 70MG/VIAL [RLD]
Has a generic version of Cancidas been approved?
No. There is currently no therapeutically equivalent version of Cancidas available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cancidas. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Aza cyclohexapeptide compounds
Patent 5,378,804
Issued: January 3, 1995
Inventor(s): Balkovec; James M. & Black; Regina M. & Bouffard; Frances A.
Assignee(s): Merck & Co., Inc.
Aza cyclohexapeptide compounds are disclosed with a nitrogen attached to the cyclohexapeptide ring at the 5-carbon of the 4-hydroxyornithine component. Such compounds are represented by the formula: ##STR1## The compounds are disclosed as having antifungal, antiprotozoal and anti-Pneumocystis carinii activity.
Patent expiration dates:
- March 16, 2013
✓
Drug substance
- September 16, 2013
✓
Pediatric exclusivity
Aza cyclohexapeptide compounds
Patent 5,514,650
Issued: May 7, 1996
Inventor(s): Balkovec; James M. & Black; Regina M. & Bouffard; Frances A.
Assignee(s): Merck & Co., Inc.
Ceretain aza cyclohexapeptide compounds have been found to have superior antibiotic properties. Novel processes for their preparation are also described.
Patent expiration dates:
Aza cyclohexapeptide compounds
Patent 5,792,746
Issued: August 11, 1998
Inventor(s): Balkovec; James M. & Bouffard; Frances Aileen & Black; Regina M.
Assignee(s): Merck & Co., Inc.
Ceretain aza cyclohexapeptide compounds have been found to have superior antibiotic properties. Novel processes for their preparation are also described.
Patent expiration dates:
Antifungal compositions
Patent 5,952,300
Issued: September 14, 1999
Inventor(s): Nerurkar; Maneesh J. & Hunke; William A. & Kaufman; Michael J.
Assignee(s): Merck & Co., Inc.
The invention is a pharmaceutical composition for intravenous administration to a patient comprising a) a pharmaceutically effective amount of a compound having the formula ##STR1## and the pharmaceutically acceptable salts thereof; b) a pharmaceutically acceptable amount of an excipient such as a bulking agent effective to form a lyophilized cake; and c) a pharmaceutically acceptable amount of acetate buffer effective to provide a pH of between about 4 and 7.
Patent expiration dates:
- March 28, 2017
✓
Drug product
- September 28, 2017
✓
Pediatric exclusivity
Antifungal compositions
Patent 6,136,783
Issued: October 24, 2000
Inventor(s): Neururkar; Maneesh J. & Kaufman; Michael J. & Hunke; William A.
Assignee(s): Merck & Co., Inc.
The invention is a pharmaceutical composition for intravenous administration to a patient comprising a) a pharmaceutically effective amount of a compound having the formula ##STR1## and the pharmaceutically acceptable salts thereof; b) a pharmaceutically acceptable amount of an excipient such as a bulking agent effective to form a lyophilized cake; and c) a pharmaceutically acceptable amount of acetate buffer effective to provide a pH of between about 4 and 7.
Patent expiration dates:
See also...
- Cancidas Consumer Information (Wolters Kluwer)
- Cancidas Consumer Information (Cerner Multum)
- Cancidas Advanced Consumer Information (Micromedex)
- Cancidas AHFS DI Monographs (ASHP)
- Caspofungin Consumer Information (Wolters Kluwer)
- Caspofungin Consumer Information (Cerner Multum)
- Caspofungin Intravenous Advanced Consumer Information (Micromedex)
- Caspofungin Acetate AHFS DI Monographs (ASHP)
